Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1997-3-14
|
pubmed:abstractText |
One of the virulence factors of the protozoan parasite Leishmania major is the surface glycoconjugate, lipophosphoglycan (LPG). A Ricin-resistant mutant of L.major was generated and characterised with respect to its virulence in mice and the structure and expression of LPG. The LPG from this mutant (1F6-B5) retained the tripartite structure of wild-type LPG, comprising a glycosylphosphatidylinositol (GPI) anchor linked to a phosphorylated disaccharide backbone terminating in a nonreducing neutral oligosaccharide cap. The structure of the GPI anchor and the major capping oligosaccharide were identical to wild-type LPG. However, there were variations in the number of phosphorylated repeats (PO4-6Gal(beta 1-4)Man(alpha 1-) comprising the backbone of LPG, although the degree of substitution with side branches (approx. 95%) was similar to that of wild-type LPG. Thus, the mutant LPG was shorter in length having, on average, 15 repeat units per molecule compared with 30 in the wild-type LPG. The mutant LPG contained both arabinose (Ara(beta 1-2)[Gal(beta 1-3)-]1,2) and galactose ([Gal(beta 1-3)-]1-8) capped side branches linked to the backbone. In contrast to wild-type LPG, the number of arabinose-capped side chains was significantly reduced, and a new population of galactose-capped (Gal(beta 1-3)]5-8) side branches was present. The level of LPG expression in mutant parasites was approximately one-tenth of the wild-type parasite. The mutant parasites were avirulent in mice. Over a period of 18 months, they did not cause lesions and organisms could not be isolated from the draining lymph nodes.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0959-6658
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
6
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
387-97
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8842702-Animals,
pubmed-meshheading:8842702-Carbohydrate Sequence,
pubmed-meshheading:8842702-Chromatography, High Pressure Liquid,
pubmed-meshheading:8842702-Chromatography, Ion Exchange,
pubmed-meshheading:8842702-Drug Resistance,
pubmed-meshheading:8842702-Female,
pubmed-meshheading:8842702-Glycosphingolipids,
pubmed-meshheading:8842702-Leishmania major,
pubmed-meshheading:8842702-Mass Spectrometry,
pubmed-meshheading:8842702-Mice,
pubmed-meshheading:8842702-Mice, Inbred BALB C,
pubmed-meshheading:8842702-Mice, Inbred C3H,
pubmed-meshheading:8842702-Molecular Sequence Data,
pubmed-meshheading:8842702-Mutation,
pubmed-meshheading:8842702-Ricin
|
pubmed:year |
1996
|
pubmed:articleTitle |
Characterization of lipophosphoglycan from a ricin-resistant mutant of Leishmania major.
|
pubmed:affiliation |
Walter and Eliza Hall Institute of Medical Research, Post Office Royal Melbourne Hospital, Victoria, Australia.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|